ANAL FISSURES {#sec1-1}
=============

An anal fissure is a defect in the epithelium of the anal canal from the ano-cutaneous border to the linea dentata. Chronic fissures are characterised by a sentinel tag, hypertophic anal papillae, anal spasm, and/or fibrosis of the inner sphincter muscle \[[Figure 1](#F0001){ref-type="fig"}\]. Chronic fissures are commonly seen at 6 o'clock with the patient in a recumbent position; fissures at any other position need further investigation as to the underlying cause. Possible causes are Crohn's disease, anal intercourse, sexually transmitted disease, or anal carcinoma \[[Table 1](#T0001){ref-type="table"}\].\[[@CIT1][@CIT2]\]

![Chronic anal fissure and marisca](JCAS-01-58-g001){#F0001}

###### 

Diseases associated with chronic anal fissures

  -------------------------------------------------------------------------------------
  Chronic inflammatory gut diseases (Crohn's disease, colitis ulcerosa)
  Chronic infections (tuberculosis and other mycobacterial infections, HIV, syphilis)
  Solid tumours (anal carcinoma and other carcinomas)
  Haematologic diseases (leukaemia, lymphoma, plasmocytoma)
  Chemo- or radiotherapy
  Trauma
  -------------------------------------------------------------------------------------

Relaxation of the sphincter internus can be inhibited by nonadrenergic, noncholinergic enteric neurons, parasympathetic muscarinic receptors, sympathetic beta receptors, or by inhibition of intracellular calcium uptake.\[[@CIT3]\]

Acute anal fissures are extremely painful during defecation; the pain is cramp-like and may persist for hours. With chronic anal fissures, the pain may be less intense during defecation, but increases after that. Perianal eczema is often associated with chronic anal fissures. Hyperhidrosis of the anal fold aggravates these symptoms.\[[@CIT4]\]

The aetiopathogenesis of the chronic anal fissure is not well understood. There is increased intraanal pressure at rest that might contribute to an ischemic state of the anal sphincter muscles. Indeed, the anodermal blood flow of the posterior midline has been shown to be reduced.\[[@CIT1]\] On the other hand, there is an increased local innervation.\[[@CIT5]\] One's established a devil's circle of spasm and pain develops.

BOTULINUM TOXIN A {#sec1-2}
=================

Botulinum toxin A (BTX A) is produced by *Clostridium botulinum* but can be synthesised as a single chain polypeptide of \~150 kDa that acts as a zinc-dependent endopeptidase. BTX A cleaves SNAP-25, a part of the SNARE complex that is responsible for acetylcholine transport from the nerve to the muscle end plate.

BTX action on hyperactive smooth muscles such as the anal sphincter is mediated by its action on the autonomic nervous system (as in striated muscles). The treatment goal for BTX is the interruption of the internal sphincter spasm and thereby, the ischemic state. Indeed, sphincter manometry after BTX injection has demonstrated a lowering of resting intranal pressure.\[[@CIT6]\]

SELECTION OF PATIENTS {#sec1-3}
=====================

The diagnosis of a chronic anal fissure has to be established by proper examination and underlying diseases need appropriate therapy. None of the available BTX products on the market has been approved for the indication of anal fissures. Therefore, in its current status, this is an off-label use for BTX A. Hence, the patient should be properly counselled with an extensive verbal and written explanation, and his/her verbal and written consent obtained.

General contraindications for the use of BTX have to be considered before its use \[[Table 2](#T0002){ref-type="table"}\].\[[@CIT7]\]

###### 

Contraindications for botulinum toxin

  ------------------------------------------------------------------------
  **Absolute contraindications**
   Gravidity and lactation
   Haemophilia
   Any drug treatment that increases the risk of bleeding
   Myasthenia gravis
   Lambert-Eaton syndrome
   Amyotrophic lateral sclerosis
   Known allergies against any of the ingredients of commercially
   available BTX formulations (such as albumin), allergies against BTX
   itself have yet not been reported.
   Simultaneous or concommittent use of drugs such as aminoglycoside
   antibiotics (streptomycin, kanamycin, gentamycin, neomycin,
   spectinomycin etc.) since they might interfere with the metabolism of
   BTX
  **Relative contraindications**
   Fluoride infections
   Severe smokers (healing impaired, interference with clotting)
   Noncompliance
  ------------------------------------------------------------------------

BTX -- Botulinum toxin

PROCEDURE OF BTX ADMINISTRATION {#sec1-4}
===============================

BTX is available in a freeze-dried form. Published studies have been performed with either Botox® (Allergan) or Dysport® (Ipsen-Speywood). One Botox®-unit translates into two or three Dysport®-units. The vials have to be resolved with sterile physiological sodium chloride solution (according to the manufacturer's instructions with 2--2.5 mL). Higher concentrations might be necessary in individual cases.

For injections, easy-to-use syringes such as the insulin syringes or those used for hyposensitization are preferred. They have a maximum capacity of 1 mL and markings that allow safe injections of volumes as low as 0.1 mL, which is the usual volume to inject per site. A fine and sharp needle of 27--32 gauge should be employed to minimize pain and bleeding.\[[@CIT2]\]

Injection should be done with the patient lying on one side or in a recumbent position. An intramuscular injection is performed after local disinfection. Injections into both the internal as well as the external sphincter muscles have been described in literature. For the former technique, the doctor has to put 2--3 fingers *in ano* for the exact localization of the needle. This technique causes more pain for the patient and also carries the risk of needle stick injury for the doctor as well. Therefore, sedation of the patient is often necessary. Injection into the external sphincter avoids these risks and sedation is not necessary. However, as the internal sphincter is also involved in the pathophysiology of anal fissures, injection into only the external sphincter may not be fully effective in releiving the spasm. However, BTX shows a three-dimensional diffusion of about 2 cm, which is considered adequate to reach the internal sphincter as well.\[[@CIT8]\]

The injections are usually placed along the fissure on both sides at a distance of 1--2 cm as fissure-associated ischaemia will prevent diffusion. In a recent study, Maria *et al*. demonstrated that a perifissural injection in the posterior-median localization is less effective than an injection along the anterior midline. They observed an increased relaxation effect by the latter technique.\[[@CIT9]\]

Different dosage schedules have been used. Most investors use higher dosages as the response rate is higher and the relapse rate is lower. Up to 100 U BTXA (Botox®) have been used without any severe adverse effects; the usual initial dosage is 20--40 U Botox® or 50--100 U Dysport®.\[[@CIT8]\]

OUTCOME AND SAFETY: PUBLISHED STUDIES {#sec1-5}
=====================================

BTX therapy of chronic anal fissures has been performed for more than ten years now and a number of mostly single-centre studies have been published \[[Table 3](#T0003){ref-type="table"}\]. The healing rates (≤ 6 months) are 60--90% and partial responses are seen in many patients. However, nonresponders are rare (\< 5%) resulting mostly due to incorrect technique and/or diagnosis. The earliest effect is the antipruritic effect. It is important to note that fissure healing often takes more time than pain relief. Long-term outcomes (\>12 months) show complete healing rates of about 50%.\[[@CIT8]\]

###### 

Selection of internationally published studies using botox in chronic anal fissure

  Author(s)                         Year   No. of patients   Units/ Injection into[\*](#T000F1){ref-type="table-fn"}   Complete response (%)
  --------------------------------- ------ ----------------- --------------------------------------------------------- -----------------------
  Gui *et al*.\[[@CIT14]\]          1994   10                15 B/IAS                                                  90
  Jost and Schimrigk\[[@CIT15]\]    1994   12                5 B/EAS                                                   83
  Jost *et al*.\[[@CIT16]\]         1995   54                5 B/EAS                                                   78
  Jost\[[@CIT17]\]                  1997   100               2.5 B/EAS                                                 82
  Maria *et al*.\[[@CIT18]\]        1998   15                20 B/ISA                                                  73
                                           15                NaCl                                                      13
  Maria *et al*.\[[@CIT19]\]        1998   23                15 B/IAS                                                  100
                                           34                20 B/IAS                                                  100
  Minguez *et al*.\[[@CIT20]\]      1999   23                10 B/IAS                                                  83
                                           27                15 B/IAS                                                  78
                                           19                21 B/IAS                                                  90
  Brisinda *et al*.\[[@CIT21]\]     1999   25                20 B/IAS                                                  96
                                           25                Nitroglycerin                                             60
  Fernandez *et al*.\[[@CIT22]\]    1999   76                40 B/IAS                                                  67
  Maria *et al*.\[[@CIT9]\]         2000   25                20 B/IAS posterior                                        80
                                           25                20 B/IAS anterior                                         100
  Lysy *et al*.\[[@CIT23]\]         2001   15                20 B/IAS                                                  73
                                                             \+ Nitroglycerin                                          
                                           15                20 B/IAS                                                  60
  Madalinski *et al*.\[[@CIT24]\]   2001   14                25--50 B/EAS                                              54
  Brisinda *et al*.\[[@CIT25]\]     2002   75                20 B (+20)/IAS                                            89
                                           75                30 B (+50)/IAS                                            96
  Trcinski *et al*.\[[@CIT26]\]     2002   13                100 D/IAS                                                 85
  Colak *et al*.\[[@CIT27]\]        2002   3                 30 B/IAS                                                  71
                                           28                Lidocain                                                  21
  Wollina *et al*.\[[@CIT4]\]       2002   5                 20--25 B/EAS                                              40
                                           5                 20--25 B/EAS                                              100
                                                             \+ 30--50 B for hyperhidrosis                             
  Mentes *et al*.\[[@CIT28]\]       2003   61                20--30 B/IAS                                              87
                                           50                Sphincterotomy                                            98
  Siproudhis *et al*.\[[@CIT29]\]   2003   22                100 B/IAS                                                 32
                                           22                NaCl                                                      32
  Lindsey *et al*.\[[@CIT30]\]      2003   40                20 B/IAS                                                  43
  Giral *et al*.\[[@CIT31]\]        2004   10                30 B/IAS                                                  70
                                           11                Sphincterotomy                                            82
  Godevenos *et al*.\[[@CIT32]\]    2004   45                25 B/IAS                                                  18
                                           37                2 × 25 B/IAS                                              78
  Arroyo *et al*.\[[@CIT2]\]        2005   100               25 B/IAS                                                  47
  Arroyo *et al*.\[[@CIT33]\]       2005   40                25 B/IAS                                                  45
                                           40                Sphincterotomy                                            92
  Iswariah *et al*.\[[@CIT34]\]     2005   17                40 B/IAS                                                  41
                                           21                Sphincterotomy                                            91
  Massoud *et al*.\[[@CIT35]\]      2005   25                20 B/IAS                                                  64
                                           25                Sphincterotomy                                            100
  Kinney *et al*.\[[@CIT36]\]       2006   22                100 B/intraanal                                           91
  Floyd *et al*.\[[@CIT37]\]        2006   32                60 B/IAS                                                  63
  Tranqui *et al*.\[[@CIT38]\]      2006   50                30--100 B/IAS                                             94
                                                             \+ Nifedipin                                              
  Witte *et al*.\[[@CIT39]\]        2007   100               40--100 D/IAS                                             77
  Radwan *et al*.\[[@CIT13]\]       2007   38                10--20 B/IAS                                              89

IAS - internal anal sphincter; EAS - external anal sphincter; B - Botox®; D - Dysport®

Complications {#sec2-1}
-------------

Faecal incontinence is a severe adverse effect of surgery. With BTX, mild temporary incontinence of flatus has been reported in ≤ 6% of the patients.\[[@CIT10]\] Abscess formation is very rare, whereas this adverse effect is seen in about 13% of lateral sphincterotomy patients.\[[@CIT11]\] Jost *et al*. reported a single case of perianal thrombosis after BTX injection into the external sphincter muscle.\[[@CIT12]\] Radwan *et al*. reported two patients with temporary faecal soiling after BTX injection into the internal sphincter muscle.\[[@CIT13]\]

Comparison of BTX to other established treatments and combinations {#sec2-2}
------------------------------------------------------------------

The gold standard for the management of recalcitrant chronic anal fissures has been lateral sphincterotomy. In a retrospective evaluation of 562 chronic anal fissure patients, complete healing was achieved within 31 weeks compared to 56 weeks with BTX. The relapse rate in the BTX group was significantly higher (35%), with 7% eventually treated by surgery.\[[@CIT37]\]

In a meta-analysis, Sajid *et al*. compared surgical *vs* chemical sphincterotomy using BTX for the treatment of chronic anal fissures. Surgical sphincterotomy had a significantly higher healing rate \[*P* \< 0.0110\] and a significantly lower recurrence rate \[*P* \< 0.0221\] than BTX. However, there was a higher complication rate \[*P* \< 0.0163\] and a higher risk of transient faecal incontinence \[*P* \< 0.0001\] in the sphincterotomy group than in the BTX group.

Scholz *et al*. treated 40 patients with combined fissurectomy followed by injection of 10 U of Botox® into the internal anal sphincter on both sides of the fissure. At six weeks, 38 patients (95%) were free of symptoms and no adverse effects were detected. The response rate of questionnaires was 93%; the median follow-up was one year (0.9--1.6 years). In the long-term, recurrence was found in four patients who were treated successfully with repeated fissurectomy, BTX injections, and salvage procedures. The overall success rate of combined fissurectomy and BTX injection was 79%, this combined approach scoring as an excellent and safe procedure with low morbidity and a high healing rate for chronic fissures.\[[@CIT40]\]

Brisinda *et al*. evaluated the efficacy of BTX injection in the treatment of recurrent anal fissures following lateral internal sphincterotomy. Eighty patients were treated with botulinum toxin (30 U Botox® or 90 U Dysport®) injected into two sites of the internal sphincter. One month after injection, there was complete healing in 54 patients (68%). Eight patients (10%) reported mild incontinence of flatus that disappeared spontaneously within two months. At two months, 59 patients (74%) had a healing scar. Anorectal manometry at one month demonstrated a significant reduction in both resting anal pressure and maximum voluntary squeeze pressure (*P* \< 0.001). There were no relapses during an average follow-up period of 57.9 months.\[[@CIT41]\]

These observations are further supported by a recent study of Baraza *et al*. in females, who have an increased risk of incontinence after surgery. The authors combined BTX injection for anal fissures with fissurectomy. Forty-six female patients who had undergone excision of the fissure edges and injection of 25--100 U of BTX (Botox®, Dysport®) into the intersphincteric space, were followed up two months after the procedure and over a period of up to 39 months. No patient had any postoperative incontinence symptoms. There was a cure rate of 85% in 44 patients at a median follow-up period of 11 months. Fissurectomy and botulinum toxin injection for the treatment of chronic anal fissure in females seems to be effective in the medium-term, but there is a high rate of late recurrence. However, only a minority of patients proceed to more invasive surgical intervention, which may make it a useful option in patients who are not suitable for lateral sphincterotomy.\[[@CIT42][@CIT43]\]

In a prospective, controlled, two-armed trial comparing 0.2% nitroglycerine nitrate ointment with 20 U Botox®, a complete healing was achieved in 66.7 or 57.1% of the patients, respectively after three months. Relapses were seen in 33% of the patients in both groups. After three years, complete healing was seen in 40.0 and 33.3% of the patients in the nitroglycerine and Botox arms, respectively.\[[@CIT44]\] The combination of nitroglycerine ointment and BTX seems to potentiate the healing effect.\[[@CIT45]\] The combination of nifedipin and BTX (30--100 U Botox®) resulted in a remarkable low relapse rate of 2% (*n* = 47).\[[@CIT38]\]

In a meta-analysis, Sajid *et al*. compared the effectiveness of BTX and glyceryltrinitrate (GTN) for the pharmacological management of chronic anal fissures (CAF). BTX and GTN were equally effective in healing/improving chronic anal fissures. GTN was associated with a higher incidence of total side effects \[*P* = 0.0002\], especially headache \[*P* = 0.0007\]. Their conclusion was that BTX is as effective as GTN for the management of chronic anal fissures, but that it is associated with a lower complication rate. BTX has therefore been recommended as a first-line therapy for chemical sphincterotomy.\[[@CIT46]\]

GUIDELINES FOR THE PRACTICE {#sec1-6}
===========================

The management of patients with chronic anal fissures involves both general and local measures. The treatment needs experience and skills and should be carried out only by those specialized in proctology. In Europe, proctology is performed by dermatologists, gastroenterologists, and specialized surgeons.

First-line therapy is always conservative and involves using appropriate nutrition, fluid intake, and exercises. Such treatment is easy, cheap, and safe but this remains the basis for all other treatments as well.\[[@CIT1]\]

Among conservative medical procedures, diltiazem, nifedipin, and nitroglycerine can be considered as first-line treatments. However, the effect is delayed with these treatments, and nitroglycerine has a significant risk of headaches.\[[@CIT46]\] If there is no response by eight weeks, BTX injections should be considered.

BTX is a safe and effective treatment for anal fissures. The effect is dose-dependent and technique-dependent. Doses of 20--40 U Botox® or 50--100 U Dysport® are useful as long as the patient does not suffer from anal fold hyperhidrosis, in which case, higher doses may be necessary. Both techniques: injections along both sides of a chronic fissure or along the anterior midline, are effective. There is some debate about the site of injection, as both internal and external sphincters have their advocates as mentioned earlier. The injection into the internal sphincter is supported by the pathophysiology of anal fissures, but is more difficult to give and more painful. Injection into the external sphincter is easier and less painful.\[[@CIT8]\] Combination of BTX with either nitroglycerine or nifedipin reduces relapse rates. The role of fissurectomy in conjuction with BTX needs further investigation.\[[@CIT47]\] Using this algorithm, lateral sphincterotomy can be avoided in most cases and BTX can also be used in patients with a relapse after surgical sphincterotomy.

In summary, BTX is a useful and safe alternative in the management of anal fissures. BTX does not cause any downtime for the patient and is more convenient than surgery. However, in some patients, particularly those with underlying pathologies, BTX may not be adequate and such patients may eventually need sphincterotomy.

**Source of Support:** Nil

**Conflict of Interest:** None declared.

**EDITORIAL COMMENTS**

The article is a well written review and indicates that medical therapy for chronic anal fissures may be used with a possibility of cure. The knowledge that botulinum toxin injection is a safe and effective therapy for symptomatic anal fissures is not new and has been reported in several studies. Spasm of the internal anal sphincter has been noted in association with chronic fissures for many years and therefore, the treatment logically focuses on alleviating hypertonia of the internal sphincter. The therapeutic efficacy of different doses of botulinum toxin in chronic fissures has only been reported recently. The reported results confirm that higher doses lead to higher success rates. When using botulinum toxin for the first time at fixed doses variable clinical responses can be observed. This may be due to several factors including the dilution volume used, a single or multiple strategy for injection, the presence or absence of specific antibodies, variability in the amount of active drug present in a single vial, the susceptibility of cholinergic cells to neurotoxin, the ability of these cells to bind and internalize the toxin, as well as the presence of an appropriate intracellular target.

It has been observed that injections of botulinum toxin into the external anal sphincter are also effective for treating fissures. The mechanism is probably mediated by diffusion to the internal sphincter, as shown by the observation that maximum squeeze pressure and resting pressure are both reduced with this procedure. As the fundamental pathogenic event in chronic fissures is the spasm of the internal anal sphincter, the injection into the external sphincter is obviously not the first choice for treatment. In addition, every procedure has a learning curve.

Different factors may influence the response to BTX. It has been found that patients with posterior chronic anal fissures show better results, represented by a lowering of resting anal tone and production of an earlier healing scar. These were achieved when botulinum toxin was injected anteriorly into the internal anal sphincter. The different injection sites induce variable decreases in resting pressure and different rates of clinical outcome. These effects should be related to the fibrosis of the internal anal sphincter that is more prominent in the site of the fissure than other sites in the smooth muscle. The fibrosis may reduce the compliance of the internal sphincter, limiting diffusion of the toxin. Fibrosis or ischaemia in the base of the posterior fissure may also destroy the myenteric nervous fibers which are located between the circular and longitudinal smooth muscle layers for the entire extent of the internal anal sphincter.
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